期刊文献+

H5N1大流行流感疫苗的研究进展 被引量:2

Progress in Research on Pandemic Influenza H5N1 Vaccine
原文传递
导出
摘要 高致病性H5N1流感病毒可导致严重的致死性疾病,对人类健康造成了极大威胁。尽管目前尚未发生人与人之间传播,但该病毒一旦与人流感病毒重组,即有可能转变为可在人与人之间传播的高致死性流感病毒,从而导致新的流感大流行。此外,H5N1流感病毒经过不断变异后可突破种属屏障,从禽类传播给哺乳动物及人类,并进一步在病毒和宿主的多种因素作用下导致宿主发病乃至死亡。本文对H5N1大流行流感疫苗的研究进展作一综述。 Highly pathogenic avian influenza H5N1 virus may cause serious fatal diseases and constitute a grave threat to human health.Although the current H5N1 influenza strains appear not to be transmissible from human to human,it is of major concern that mixing with human influenza strains could convert H5N1 to a strain that would spread that would spread from human to human and cause a serious pandemic.In addition,avian influenza H5N1 virus after continuous variation may break through the species barrier and spread to mammals and humans,thereby cause disease even death under the influence of various virus and host factors.This paper reviews the progress in research on pandemic influenza vaccine.
出处 《中国生物制品学杂志》 CAS CSCD 2011年第5期618-620,624,共4页 Chinese Journal of Biologicals
关键词 流感病毒A型 H5N1亚型 流感疫苗 Influenza virus type A Subtype H5N1 Influenza vaccine
  • 相关文献

参考文献20

  • 1Brady RC, Treanor JJ, Atmar RL, et oi. Safety and immunogenic- ity of a subvirion inactivated influenza A / H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults [J]. Vaccine, 2009, 27 (37): 5091-5095.
  • 2Alberini I, Del Tordello E, Fasolo A, et al. Pseudoparticle neu- tralization is a reliable assay to measure immunity and cross-reac- tivity to H5N1 influenza viruses [J]. Vaccine, 2009, 27 (43): 5998-6003.
  • 3Forrest HL, Khalenkov AM, Govorkova EA, et al. Single- and muhiple-clade influenza A H5N 1 vaccines induce cross protection in ferrets [J]. Vaccine, 2009, 27 (31): 4187-4195.
  • 4Ehrlich HJ, Mfiller M, Oh HM, et al. A clinical trial of a whole- virus H5N1 vaccine derived from cell culture[J]. N Engl J Med, 2008, 358 (24): 2573-2584.
  • 5Evseenko VA, Bukin EK,Zaykovskaya AV, et al. Experimental infection of H5N1 HPAI in BALB/c mice [Jl. Virol J, 2007, 4 ( 1 ) : 77-84.
  • 6Peiris JS, De Jong MD, Guan Y. Avian influenza virus (H5N1): a threat to human health [J]. Clin Microbiol Rev, 2007, 20 (2): 243-267.
  • 7Rimmelzwaan GF, Sutter G. Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara [J]. Vaccine, 2009, 8 (4): 447-454.
  • 8Hu AY, Weng TC, Tseng YF, et al. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines [J]. Vaccine, 2008, 26 (45): 5736-5740.
  • 9Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data [J ]. Ex- pert Opin Biol Ther, 2009, 9 (8): 1057-1071.
  • 10Galli G, Medini D, Borgogni E, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term per- sistence of protective antibody levels [J]. Proc Natl Acad Sci US- A, 2009, 106 (10): 3877-3882.

同被引文献34

  • 1郭元吉.高致病性禽流感研究进展[J].中华实验和临床病毒学杂志,2006,20(2):90-93. 被引量:46
  • 2Collins PJ, Haire LF, Lin YP, et al. Crystal structures of osel- tamivir-resistant influenza virus neuraminidase mutants[J]. Nature, 2008, 453(7199):1258-1261.
  • 3Yon Itzstein M, Wu WY, Kok GB, eta/. Rational design of potent sialidase-based inhibitors of influenza virus replica- tiot[J] Nature, 1993, 363(6428):418-423.
  • 4Satoh N, Aklba T, Yokoshima S, et al. A practical synthesis of (-)-osehamivir[J]. Angew Chem Int Ed Engl, 2007, 46(30): 5734"5736.
  • 5Babu YS, Chand P, Bantia S, et al. BCX-1812(RWJ- 270201): Discovery of a Novel, Highly Potent, Orally Active and Selective Influenza Neuraminidase Inhibitor through Structure-Based Drug Design[J]. J Med Chem, 2000, 43(19): 3482-3486.
  • 6Yamashita M, Tomozawa T, Kakuta M, et al. CS-8958, a pro- drug of the Neuraminidase Inhibitor R-125489, shows long- acting anti-influenza virus activity[J]. Antimierob Agents Chemother, 2009, 53(1):186-192.
  • 7Yacine Abed, Mariana Baz, Guy Boivin. Impact of neuramini- dase mutations conferring influenza resistance to neuramini- dase inhibitors in the N1 and N2 genetic background[J]. An- tiviral Therapy, 2006, 11(8): 971-976.
  • 8Thanyada Rungrotmongkol, Pathumwadee Intharathep, Ma- turos Malaisree, et al. Susceptibility of antiviral drugs against 2009 influenza A(H1N1) virus[J]. Biochemical and Biophysi- cal Research Communications, 2009, 385(3):390-394.
  • 9Mitrasinovic PM. Advances in the structure-based deSign of the influenza A Neuraminidase inhibitors[J]. Curr Drug Tar- gets, 2010, 11 (3):315-326.
  • 10Russell R J, Haire LF, Stevens D J, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportu- nities for drug design[J]. Nature, 2006, 443(7107):45-49.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部